RxDoctor Payments Data

Catherine Estipona

Family · Reno, NVNPI 1760556534

Payments from drug & device makers

$3,060in general payments, 2019–2025

Across 180 payments — averaging $17.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$853
  • GSK$476
  • Novo Nordisk$251
  • Pfizer$214
  • AstraZeneca$148
  • Lilly USA, LLC$134
  • plus $984 from 21 others

What the payments were for

  • Food & beverage$3,060100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,060 in reported general payments places this provider in the 85th percentile of 1,501 family providers in Nevada.

See all family providers in Nevada

Medicare billing

Part B allowed, 2024
$52,049
Medicare patients
148
Services billed
542

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TradjentaLinagliptin78$97,643
JardianceEmpagliflozin65$94,930
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$39,419
FarxigaDapagliflozin Propanediol14$19,575
EliquisApixaban13$18,851
Breo ElliptaFluticasone/Vilanterol32$18,010
OzempicSemaglutide11$17,701
MovantikNaloxegol Oxalate15$13,841
Rosuvastatin Calcium208$4,675
Tolterodine Tartrate ErTolterodine Tartrate24$3,594
Levothyroxine Sodium298$3,062
Atorvastatin Calcium183$2,742
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$2,292
Ezetimibe104$2,106
Albuterol Sulfate HfaAlbuterol Sulfate62$2,081

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimTradjenta, Jardiance$91$192,573143 claims
GSKTrelegy Ellipta, Breo Ellipta$476$57,42958 claims
AstraZenecaFarxiga$148$19,57514 claims
PfizerEliquis$214$18,85113 claims
Novo NordiskOzempic$251$17,70111 claims
AbbVieSynthroid$853$1,03527 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,501 family providers in Nevada.

Other family in Reno

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →